Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Enrolling by invitation Observational

Comparative Study of Laparoscopic Combined Trans-vesical and Extravesical Versus Laparoscopic Extravesical Fistula Excision in Uterovesical Fistula Repair: A Retrospective Observational Study

NCT06803160 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2025-01-30
Last updated
2025-01-31

Condition(s) studied

Success of Operation

Investigational drug(s) / intervention(s)

Laparoscopic Extravesical Fistula Excision of Uterovesical FistulaLaparoscopic Combined Fistula Excision of Uterovesical Fistula

Laparoscopic Extravesical Fistula Excision of Uterovesical Fistula: • In extravesical approach, the posterior bladder wall and the anterior uterine wall around the fistula will be dissected. Scar tissue around the orifice of the fistula will be removed and trimmed. After suturing uterine and bladder wall, intervening omentum will be placed in-between.

Laparoscopic Combined Fistula Excision of Uterovesical Fistula: • In the combined approach, bladder will be opened bivalved till the site of the fistula. Scar tissue around the orifice of the fistula will be removed and trimmed. Careful dissection around the bladder and uterus will be done to suture both walls and place an intervening omentum in-between.

Study summary

• The aim of this study is to compare between laparoscopic combined trans-vesical and extravesical versus laparoscopic extravesical fistula excision in uterovesical fistula repair.

Eligibility

Sex
FEMALE
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: Patients diagnosed with uterovesical fistula with history of uterine cesarean section or any urogenital surgery complaining of amenorrhea, cyclic hematuria, with or without urinary incontinence. Exclusion Criteria: * • Pregnant females. * Patients who refuse to participate in the study. * Patients with concomitant pathology that could affect symptoms e.g., polycystic ovary disease, stress incontinence, bladder cancer or overactive bladder. * Patients with malignant fistula.

Primary outcome measure(s)

  • success of operation — 6 months
    Success of operation with excision of fistula in upcoming CT cystogram

Trial sites (1)

FacilityCityRegionStatus
Ain Shams University Cairo Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06803160 on ClinicalTrials.gov ↗ ← All trials in Egypt